Fixing Genetic Diseases at the Source
After decades of failures and tragedy (Jesse Gelsinger’s 1999 death halted trials for years), gene therapy finally delivered dramatic successes in the 2010s-2020s. The approach: directly correcting genetic defects by inserting functional genes, editing faulty ones, or silencing harmful mutations. FDA approvals accelerated from near-zero before 2017 to 15+ treatments by 2023 for conditions previously untreatable.
Landmark Cures
Luxturna (2017): First FDA-approved gene therapy for inherited blindness (RPE65 mutation), injecting functional genes into retinas—patients who were legally blind gained sight. Zolgensma (2019): One-time $2.1 million treatment for spinal muscular atrophy (SMA), replacing defective SMN1 gene—babies expected to die by age 2 now develop normally. CRISPR sickle cell cure (2023): First CRISPR therapy editing patients’ blood stem cells, eliminating painful crises—functional cure for previously lifelong genetic disease.
Hemophilia Breakthroughs
Hemophilia A & B gene therapies (2022-2023 approvals) transformed bleeding disorders requiring lifelong infusions (costing $300K-900K annually) into one-time cures. Patients who needed clotting factor injections 2-3 times weekly now produce their own Factor VIII/IX after a single gene therapy infusion. Years-long follow-up shows sustained benefits, though durability over decades remains uncertain.
The Price Problem
Gene therapies cost $500K-$3.4M per treatment—among the most expensive medicines ever. Manufacturers justify prices citing decades of R&D, small patient populations, and one-time cure economics (vs. lifelong treatments). Insurers struggle with paying millions upfront for cures vs. thousands annually for symptom management. Outcomes-based payment models (pay only if treatment works) and global access inequities (therapies unavailable in developing countries) create ethical dilemmas about who deserves genetic cures.
Sources:
- FDA gene therapy approvals: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
- NEJM SMA results:
- Nature CRISPR sickle cell: https://www.nature.com/articles/d41586-023-03590-6